Ahwahnee Technology
Ahwahnee is a leading nanotechnology company founded in Silicon Valley in late 2002 as a force to enable the Carbon Nanotube (CNT) to become a building block in a multitude of applications and industries. Ahwahnee's industry-leading CNTs are revolutionizing a number of markets, including fuel cells, energy and semiconductors. As one of only a few companies today to commercialize CNT production, the Company's goal is to provide CNT material at an industrial scale, then to create and commercialize its own CNT application primarily targeted at the energy market.

Aridis Pharmaceuticals, LLC
Aridis is a private biologics drug development company (formed in 2003) using formulation and delivery technologies to provide differentiated, high value products. Our mission is to address important diseases that have a significant impact on life expectancy, such as infectious diseases in children. Our solution lies in producing dried biologicals that are stable at room temperature and administered in “ready-to-use” formats. For example, an oral rotavirus vaccine in a quick dissolving wafer not only can prevent 500,000 childhood deaths worldwide each year, but also offers an attractive market in the US and Europe. Similar advantages apply with chronic antibody therapeutics designed for home treatment, e.g., an inhaled antibody for chronic lung infections in cystic fibrosis patients where a more convenient and reliably stable therapy would be a significant advancement. In each market, Aridis’ is dedicated to providing products with greater convenience and less cost to healthcare organizations and the patient.

BioMarker Pharmaceuticals, Inc.
BioMarker is translating the discovery of genes that control aging into innovative therapeutics and diagnostics that can treat or prevent chronic diseases associated with aging. Therapeutic interventions based on these genes will result in a longer and healthier human lifespan. When experimental animals are fed diets that are severely restricted in total calories they exhibit a potent protection against age-related diseases like cancer, heart disease, metabolic disorders like diabetes, and neurodegenerative diseases like Alzheimer’s and Parkinson’s disease. In addition, their maximum lifespan is extended by about 30%. This approach, called calorie restriction (CR), is far too difficult to be readily adopted by people. BioMarker is identifying “CR mimetics”, which will have the same properties as CR itself. BioMarker has developed a proprietary screening approach to identify CR mimetics. We intend to deliver safe and efficacious therapeutics and wellness products to enable people to live much longer, productive and healthier lives.

BrighTex Bio-Photonics
BrighTex Bio-Photonics (BTBP) develops and enhances the detection of early skin conditions and diagnostics through imaging, utilizing algorithms for early signature analysis specific to the area of biosciences and industrial applications. BTBP partnerships allow companies to enhance the capability of their imaging systems.

The California Center for Healthcare and Biomedical Technology
The California Center for Healthcare and Biomedical Technology is a Center of Excellence dedicated to high quality, comprehensive biomedical research and patient treatment and care.
The fully integrated biotechnology hospital will focus heavily on patients with musculoskeletal, cardiovascular, and oncology-related disorders, and provide specialization in other areas such as urology, gynecology, general surgery, podiatry, and gastroenterology. Dedicated to medical innovation, the hospital will have access to state-of-the-art surgical and imaging equipment, as well as medical procedures. The center will also have a Research Foundation, which will focus on providing tomorrow's therapies today via physician-led clinical trials, relationships with device manufacturers, and sponsored medical conferences. Through forming strategic local alliances and providing a forum for delivery, CCHBT will create a unique, aggressive research-focused hospital.
This project will redefine the delivery of healthcare and innovative medicine by capitalizing upon trends that are developing in the fragmented healthcare market, by delivering to the physician the control over patient care and services.

Cardiva Medical, Inc.
Cardiva's first product, the Boomerang Wire, was approved in EU countries and in the US in 2004 and brought to market in 2005. Our second generation product, the Boomerang Catalyst System, was launched recently in July 2007. This product uniquely provides the control to achieve rapid hemostasis with early patient ambulation as well as the confidence to leave nothing behind, eliminate implant-related complications and allow immediate re-access. To support clinicians in effectively using the technology and in adopting best practices in and out of the lab, the Company further provides its comprehensive Pathway Program, consisting of ongoing, extensive clinical education and outcomes monitoring resources.

ChiroSolve, Inc.
ChiroSolve is a multi-faceted company providing assistance in various aspects of organic and chiral chemistry research. It offers chemical kits named ChiroSolv® that speed up chiral research and pre-manufacturing cycle by up to 90%. The kits help researchers who use the resolution by Diastereomeric crystallization and can be used with racemates of type acid, base, alcohols, amino acids, aldehyde and ketones. ChiroSolv® consists of a set of six chemical kits, each containing 96 vials that are filled with a unique combination of resolving agents and solvents in pre-calibrated quantities. As a result, scientists using all six types of kits can potentially screen 96 X 6 = 576 combinations of the resolving agents and solvents in a single sitting.

Chronix Biomedical, Inc.
Chronix is a genomics company that designs simple blood tests targeted at the earliest detection of chronic illnesses. Chronix’s first product, an ante mortem blood test for Bovine Spongiform Encephalopathy (“BSE” or “mad cow disease”), is currently in validation studies by the German and Canadian governments. Chronix also intends to pursue molecular diagnostic applications for variant Creutzfeldt-Jakob Disease (“vCJD”) and several cancers, including breast, lung, ovarian, and prostate. The Company has offices in San Jose, California and laboratories in Brookings, South Dakota and Göttingen, Germany.

ConfometRx
ConfometRx is pioneering a platform of structure-based drug development tools that facilitate target validation, lead identification, and lead optimization for G protein coupled receptor (GPCR) targets. This platform includes biochemical and biophysical technologies for defining drug binding sites; the production of pure, functional GPCRs for high-resolution structure determination by crystallography and NMR; the generation of receptor-specific, functional antibodies for target validation and therapeutics; and ConfoScreen, a set of novel screening and assay technologies.

DEVRO Medical
DEVRO Medical Ltd is a supplier of Australian Purified Collagen formulations (ISO 13485, EDQM CEP accredited). We have increased our presence in the United States with the opening of an applications lab and distribution center in the San Jose BioCenter, CA. Our aim is to facilitate the use of our fully traceable, Australian bovine collagen, while providing the technical support and local distribution our customers require. DEVRO Medical’s mission is to produce consistent, high quality collagen products and to form effective partnerships with our customers.

Edison Pharmaceuticals
Edison's business is the development of drugs to treat diseases that impair energy metabolism. Energy impairment diseases can be classified on the basis of whether they are inherited or acquired, and furthermore on the location of the defect. Edison is initially focusing on inherited diseases of the mitochondria- nature's biological energy substation. The understanding of mitochondrial genetic diseases is being accelerated with genetic tools and is allowing for the characterization of heretofore-uncharacterized energy impairment diseases. Inherited mitochondrial diseases account for over 100 human diseases and alone affect an estimated 100,000 persons worldwide for whom there are no approved drugs.

Elixir Institute of Regenerative Medicine
The Elixir Institute of Regenerative Medicine (EIRM) was founded with a vision to create one of the first non-profit, non-academic, exclusively stem cell focused research institutes in the US to accelerate progress in this nascent field.

Epitex BioSystems
Epitex BioSystems is developing an improved method for genetic engineering of mammalian cells. Our proprietary technology will reduce the time required to make high yield recombinant cell lines from months to days. The continuous expression and scalability of a stable cell line make this method the fastest way to produce recombinant protein candidates for biotech research programs. Our technology can also be applied to cell based screening and therapeutic protein (and antibody) manufacturing. We are a concept stage company with patent pending engaged in demonstrating proof of principle.

Fast Light Laboratories

GenePrism, Inc.
A large number of single nucleotide polymorphisms (SNPs) have been found in the genes encoding drug metabolizing enzymes, and pharmacogenetic studies have shown many of them to be important determinants of inter-individual variability in drug response. GenePrism is developing innovative genomic and proteomic tools to systematically and comprehensively interrogate the effects of these SNPs and their gene products in drug metabolism and drug-drug interactions. GenePrism plans to commercialize its proprietary reagents, services and intellectual properties to advance pharmacogenetics-driven drug development and personalized medicine.

GIRUS Life Sciences, Inc.
GIRUS is developing innovative technologies to direct biological outcomes in tissues and tissue culture. The company’s intellectual property includes its novel Cell Trafficking Technology (CTT) developed at UC San Francisco. GIRUS’ CTT increases influx of administered human hematopoietic stem cells into the bone marrow, effectively improving success of stem cell transplants and immune recovery. GIRUS is working on advancing cell culture science and its portfolio also includes animal-free media and supplements that specifically regulate viability, growth and production of cells in culture. The company’s immediate focus is commercialization of these proprietary cell culture products to enable and accelerate manufacturing of protein therapeutics. Because they are animal-free, these products provide improved biological safety, and offer cost-effective technical solutions to a highly regulated industry.

L2B Environmental Systems Inc.
We are L2B and for over 5 years, we have helped home owners and corporations the world over improve the quality of their air. Whether your needs are big or small, custom or stock, there's an L2B system the right size and price for you. And because we are world leaders in innovative air quality systems, you get the benefit of our research & development, product design and manufacturing. L2B is your one step solution to your indoor air quality concerns. Depending upon your specific needs, we offer UVC germicidal disinfection, high reflectance UVC surface coating technology and air filtration.

MedLex
MedLex develops, markets, and sells the most advanced enterprise-wide and integrated decision support and portfolio management software and systems. Our technology represents a breakthrough in decision support and management software for the pharmaceutical, biotech, and healthcare industries. Our objective is to set the industry standard for IT-based decision support technologies.

MyeloRx LLC
MyeloRx's mission is the discovery and development of drugs for cancer and autoimmune diseases with the first target being acute myeloid leukemia. The initial drugs are derived from the Chinese herb, Tripterygium wilfordii Hook F (TWHF). Extracts of these herbs have been used classically in Chinese medicine for the treatment of autoimmune and inflammatory diseases. The company has isolated the active species of the herb, triptolide, and synthesized a number of analogues. Three patent applications have been licensed by MyeloRx and a fourth application, developed internally, has been filed. The lead compound, MRx 102, has demonstrated potent anti-cancer activity in cellular and animal model systems.

Obura Company
Obura Company is a preclinical stage company focusing on amyotrophic lateral sclerosis (ALS). Also known as Lou Gehrig's disease, ALS is a severe and debilitating disease that affects 30,000 Americans and many more people overseas. People with ALS lose their abilities to walk, to use their hands, and to eat and speak, and eventually become dependent on respirators. With average survival from diagnosis at 3 - 5 years and no truly effective treatments currently available, new therapeutic options are urgently needed. We are currently testing our lead compound, DM201, for use in ALS, and we are also investigating mechanisms of pathogenesis of this disease.

Oxford Genome Sciences Ltd
Oxford Genome Sciences (OGeS) discovers and develops targeted antibody therapeutics to deliver innovative & cost-effective medicines for major unmet patient needs in the field of oncology.

Phyllom LLC

Primity
The search for new drug candidates typically begins with high throughput screening (HTS) of combinatorial chemical libraries. Technological advances in HTS technology have greatly increased the efficiency of these screens, leading to an explosion of drug candidates. The increased production of HTS campaigns has uncovered a new bottleneck in the drug discovery process: the biological characterization of hit compounds. The larger volume of candidate compounds and the desire for more informative assays necessitates higher-throughput, high-content cell-based secondary assays. Primity Inc. has developed a cell-based secondary screening platform (HT-CBS) that can perform multiple assays on a variety of cell types simultaneously. This platform will have the same effect on secondary screening as high-throughput screening (HTS) had on small molecule drug development.

Reviva Pharmaceuticals, Inc.
Reviva Pharmaceuticals is an emerging research based pharmaceutical company focused on developing a portfolio of internally discovered next generation safe and effective therapeutic drugs by using an integrated chemical genomics-based technology platform and proprietary chemistries. The company is currently focused on developing drugs for the central nervous system (CNS), cardiovascular (CV), infectious, metabolic and inflammatory diseases.

Single Cell Technology, Inc.
Central to contemporary pharmaceutical and diagnostic development is the unrelenting pursuit of tight binding molecules, “binders” for short. Once a molecular target is identified, the search is on to find binders that attach quickly, stay on for the desired period of time, bind to the exact site and that site alone, and elicit the desired diagnostic or biological response.
Single Cell Technology (SCT) has developed and patented a proprietary and unique platform to identify and characterize antibody-based binders. With innovative integration of cutting edge technologies, we deliver in a single run thousands of binders that are carefully ranked based on kinetic properties and site binding characteristics. In addition, we obtain valuable insight into the molecular target’s structure that was previously unavailable. Based on the outcome of the initial run, we can launch additional runs to optimize a number of select candidates in parallel. In short, the SCT versatile platform delivers the best of the current hybridoma and phage display technologies without their inherent limitations.
In addition to seeking binders for pharmaceutical purposes, our platform can easily extend to other areas such as diagnostics and research where the burden of regulatory approval is much less.

Stratedigm, Inc.
Our main goal at Stratedigm is to be part of your team by offering you a tool that meets your needs today as well as in the future. Our team has spent many years working in the high tech and bio-tech industries in R&D and operations where we designed and anufactured scalable servers, light engines, consumer electronics, micro fluidics and more importantly, flow cytometers. We decided early on to create a company where our engineering team would work directly with you. To create the S1000 series, we collaborated with researchers and educators and asked what they needed in a flow cytometer. We had no sales or marketing teams involved, just a group of engineers working directly with scientists in the design and testing of the product. The result was an easy to use, very robust instrument that could be fully configurable with world class resolution, performance and sensitivity. We hope that our products will make your tasks easier and look forward to working with you.

Stratos BioSystems, LLC
Stratos Biosystems is an emerging biochip company developing novel biochips for analysis of peptides and proteins by mass spectrometry. The Company’s proprietary EC-Affinity™ Biochips for Affinity Mass Spectrometry and related products enable the routine use of mass spectrometers (MALDI TOF-MS) as protein biochip readers. These products exploit the advantages associated with label-free mass spectrometric detection while providing sensitivity and selectivity comparable to imaging biochip readers. Moreover, EC-Affinity™ Biochips enable mass spectrometric detection of post-translation modifications (PTMs) and transcript variations that are not detected by ELISA and other colorimetric methods. The Company was co founded in 2003 by Mark L. Stolowitz and Allan H. Stephan.

Tacere Therapeutics, Inc.
Tacere specializes in the development of novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C. Combining expertise in RNA interference (RNAi), gene medicine, and novel biologicals, Tacere possesses proprietary skill in the identification and development of RNAi therapeutics. Tacere is currently performing IND-enabling studies on its lead therapeutic compound, TT-033.

TricornTech Corp.

Zikon Corporation
Zikon uses proprietary REED (Reverse Emulsion Electrophoretic Display) technology to create low-cost nanotechnology-based electronic Ink for flat panel displays. Zikon’s Ink is low cost and energy efficient.

Zymera
Zymera is a biotechnology company developing key innovations for the Clinical Chemistry and Life Science Markets. Our goal is to radically increase the effectiveness, practicality, and use of biochemical detection solutions. Zymera’s products and innovations will catalyze fundamental change in our approach to solving important medical problems.